PMID- 26425337
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151001
LR  - 20231111
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 6
IP  - 5
DP  - 2015 Oct
TI  - Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and 
      opinion.
PG  - 242-52
LID - 10.1177/2040620715592569 [doi]
AB  - Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin's lymphoma typically 
      marked by an aggressive clinical course and a predilection for relapse. The 
      B-cell receptor (BCR) signaling survival pathway is chronically activated in MCL, 
      contributing to its pathogenesis. Ibrutinib is an inhibitor of Bruton's tyrosine 
      kinase, a vital component of this pathway. This article details the current 
      clinical experience with ibrutinib in the treatment of patients with MCL, 
      including completed and published clinical trials and reviews potential adverse 
      events (AEs) and pitfalls associated with ibrutinib therapy. Although most AEs 
      experienced by patients treated with ibrutinib are mild, some can be severe and 
      treatment limiting and may be attributed to off-target effects. Ibrutinib is a 
      very promising agent for patients with MCL with notable response rates. However, 
      when used as a single agent, around one third of patients relapse in the first 2 
      years of treatment. Recently reported combination therapies have shown 
      significant activity. Emerging data evaluating potential mechanisms of drug 
      resistance and the poor clinical outcomes after treatment failure are also 
      discussed. Further understanding of resistance and its implications not only in 
      relapsed disease but in the frontline setting are needed. Investigation of 
      strategies to overcome resistance remains an area of high unmet clinical need. 
      Evaluation of the impact of shorter treatment duration, effects on minimal 
      residual disease, and incorporation of novel combinations are also warranted.
FAU - Stephens, Deborah M
AU  - Stephens DM
AD  - Division of Hematology, Department of Internal Medicine, Huntsman Cancer 
      Institute, The University of Utah, 2000 Circle of Hope, Room 4246, Salt Lake 
      City, UT 84112, USA.
FAU - Spurgeon, Stephen E
AU  - Spurgeon SE
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Knight Cancer Institute at Oregon Health Sciences University, Portland, OR, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC4556969
OTO - NOTNLM
OT  - adverse events
OT  - ibrutinib
OT  - mantle cell lymphoma
OT  - resistance
COIS- Conflict of interest statement: Dr. Spurgeon: Research funding: Pharmacyclics, 
      Janssen Pharmaceuticals Inc., and Acerta Pharma. Honoraria: Pharmacyclics.
EDAT- 2015/10/02 06:00
MHDA- 2015/10/02 06:01
PMCR- 2015/10/01
CRDT- 2015/10/02 06:00
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2015/10/02 06:01 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - 10.1177_2040620715592569 [pii]
AID - 10.1177/2040620715592569 [doi]
PST - ppublish
SO  - Ther Adv Hematol. 2015 Oct;6(5):242-52. doi: 10.1177/2040620715592569.